Biopharma happenings in Asia-Pacific, such as deals and partnerships, grants, preclinical data and other news in brief, including: 4Bio Ventures, A2A, Abbvie, AGC, Alivamab Discovery, Arbor, Astrazeneca, Avita Medical, Black Cat, Cresco, CSL, Delta 4, East China Normal University, Eleva, Epivax, Exeltis Healthcare, Global Institute of Stem Cell Therapy and Research, Harbour Biomed, Healios, Heat Biologics, Ibio, Immunoprecise Antibodies, Integrated, Intravacc, Kyowa Kirin, Laxai Life Sciences, Lupin, Macure, Memo, Mitsubishi Tanabe, Modular, Novavax, Octapharma, Oncolytika, Pharmabcine, Rottapharm, Sorrento, Swift, Takis, Valirx, Vitro Diagnostics.
Fidget spinners are hand-held toys based on a roller bearing and three weighted lobes, which can spin freely, creating centrifugal force when activated manually.
The juggernaut that is Daiichi Sankyo Co. Ltd.’s Enhertu continued to roll into this weekend’s American Society of Clinical Oncology virtual meeting, bringing momentum from its December FDA approval for HER2-positive breast cancer, along with fresh data from three new studies in other indications.
HONG KONG – South Korea’s Qurient Co. Ltd., located in Gyeonggi-do, is preparing to send its novel drug, Q-702, into the clinic after receiving clearance from the U.S. FDA.
Prescient Therapeutics Pty Ltd. is poised to develop next-generation CAR T therapies after signing a deal with the University of Pennsylvania for a universal immune receptor technology platform.
With some positive early data for an antibody to block the COVID-19 virus, Sorrento Therapeutics Inc. is now looking to test a product in a few dozen intensive care patients by the end of July or early August and move into a much broader pool of patients by October.
LONDON – The World Health Organization (WHO) is stepping up its effort to try and ensure equitable access to any approved COVID-19 vaccines and therapies, putting in place a system for sharing all intellectual property, information and clinical trials data needed to enable generic manufacturing.
SUZHOU, China – With the outbreak tightly contained, business activities are starting to get back to normal in China. Opening in Suzhou on Thursday, the Enmore Bio Conference 2020 is one of the first industry galas to take place since the coronavirus hit the country. In the opening session, Chinese biotech insiders pointed to a bumpy road ahead for Chinese companies in the post-COVID-19 era.
RSS
